finance News

LONDON and NEW YORK – Huma, Europe’s fastest-growing health technology company [1], is partnering with the non-profit patient advocacy group RARE-X, which runs a collaborative patient-powered data collection platform for global data sharing and analysis to accelerate treatments for rare disease. RARE-X’s federated data platform will pair with Huma’s decentralized clinical trials platform, complete...
CARLSBAD, Calif. – Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR), facilitates early diagnosis and enhances disease management of patients living with ATTR amyloidosis. The Janice Wiesman Young...
SAN DIEGO – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect...
This spring the Moebius Syndrome Foundation will award four educational scholarships of $2,000 each, to individuals who have Moebius syndrome and will be attending an undergraduate college/university/post-secondary vocational school. Three scholarships will be awarded to undergraduates and one to a graduate student! Applications must be received by April 30, 2021....
SAN DIEGO – n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases. n-Lorem Foundation...
SAN DIEGO – n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with ChemGenes Corporation, a biotechnology company providing unparalleled expertise in the field of DNA/RNA synthesis for more than 40 years. n-Lorem Foundation is the...
Curing cancer has been the dream of countless doctors and researchers over the decades. Yet some types of cancer, whether because they affect relatively few people or lack influential advocates, receive less attention and funding than others. A recent gift to Harvard Medical School (HMS) is boosting efforts to understand...
WASHINGTON – Patients, clinicians and families facing uncertainty about their choices for managing Type 2 diabetes and rare diseases will gain new evidence to inform their decision making from comparative clinical effectiveness research (CER) studies that the Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved for a total...